NEW YORK (GenomeWeb) – ClearLight Diagnostics announced today that it has raised $3.5 million in a Series B financing round.

The round was led by a syndicate of existing investors created by Wiegers Capital Partners.

The company said it will use the proceeds of the financing to continue the development of a technology platform and associated applications using the Clarity lipid-clearing technique developed by company founder Karl Deisseroth and his colleagues at Stanford University, coupled with a microscopy method called clarity optimized light-sheet microscopy (COLM).